Oncology remained one of the strongest areas in this edition of Trial Watch, with multiple late stage and high signal programs showing clear strategic movement. The strongest signal comes from Bristol Myers Squibb advancing CD19 CAR T therapy into Phase 3 systemic sclerosis, reflecting how oncology derived cell therapy platforms are now expanding aggressively into autoimmune disease.
At the same time, competitive pressure inside hematology and immuno oncology continues to intensify as sponsors move from proof of concept studies toward differentiation driven development strategies.